GlassScriptPhysician profile
Brian K Jorgensen
NPI 1730197658
$2,373.21
in general payments reported to CMS, 2019-2025
28 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $213 · 2021: $332 · 2022: $412 · 2023: $509 · 2024: $375 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,222.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $428.76 | 2019-2025 | Evenity, Prolia, Prolia |
| Novartis Pharmaceuticals Corporation | $347.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $260.97 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $194.45 | 2021-2025 | |
| Abbvie INC. | $187.06 | 2021-2023 | |
| Lilly USA, LLC | $130.91 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $119.40 | 2022-2025 | Proclaim, Ensite, Octrode |
| Exact Sciences Corporation | $89.63 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $85.48 | 2020-2025 | Ozempic |
| Lucid Diagnostics INC. | $85.16 | 2021-2022 | |
| Allergan, INC. | $77.63 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $38.90 | 2019 | |
| Xeris Pharmaceuticals, INC. | $35.64 | 2022 | |
| Glaxosmithkline, LLC. | $29.83 | 2023-2024 | Shingrix, Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $28.68 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $28.11 | 2023 | Axonics |
| Biohaven Pharmaceutical Holding Company LTD. | $24.70 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.49 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.18 | 2024 | |
| Sanofi Pasteur INC. | $19.07 | 2020 | |
| Edwards Lifesciences Corporation | $17.71 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $15.85 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.76 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.63 | 2025 | Jardiance |
| Philips North America LLC | $15.47 | 2019 | |
| Esperion Therapeutics, INC. | $14.58 | 2020 | |
| Medicomp INC | $13.72 | 2023 | Telepatch Cardiac Monitor |
| Ibsa Pharma INC. | $13.50 | 2025 | Tirosint, Licart, Flector |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Jorgensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.